Fluorescein-Specific (FITC-E2) CAR T Cells

FITC-E2 CAR T cells · Seattle Children's Hospital

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Fluorescein-Specific (FITC-E2) CAR T Cells, covering 2025-11-20 to 2025-11-20. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma [Phase 1]

See pricing